Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Inclusion Criteria

• •Patients with measurable and pathologically confirmed advanced pancreatic cancer, including metastatic pancreatic cancer (who have received standard chemotherapy) and recurrent pancreatic cancer (who have received surgery and adjuvant chemotherapy previously).
• •Patient's tumor must express the KRAS G12V mutation, or a G12V mutation in HRAS or NRAS, as determined by DNA or RNA sequencing methods.
• •Patients must be HLA-A\*11:01.
• •Patients between 18 to 75 years old are eligible.
• •Patients should have good clinical performance status (ECOG 0 or 1).
• •Patients must practice birth control once enrolled into the study and for up to four months after therapy.
• •Patients must be seronegative for HIV antibody.
• •Patients must be seronegative for hepatitis B surface antigen and core antibody (or HBV non-detectable by QPCR).
• •Patients must be seronegative for hepatitis C antibody (or HCV non-detectable by QPCR).
• •Baseline hematology criteria:
• •* Absolute neutrophil count of at least 1000/mm\^3.
• •* White blood cell count of at least 3000/mm\^3.
• •* Platelet count of at least 100,000/mm\^3.
• •* Hemoglobin \> 8.0 g/dL.
• •Baseline chemistry criteria:
• •* Serum ALT/AST less than or equal to 3.0 x ULN.
• •* Total bilirubin less than or equal to 1.5 mg/dL, unless the patient has Gilbert's Syndrome in which case total bilirubin must be less than or equal to 3.0 mg/dL.
• •* Serum creatinine less than or equal to 1.6 mg/dL.
• •Anticipated lifespan greater than 12 weeks.
• •Patients must be willing and able to comply with all study-related procedures and follow-up requirements.
• •Patients must be able to understand and sign a written Informed Consent Document as well as a durable power of attorney.